ViRAGE: Situational Analysis of HIV-related Disability in the Context of Ivory Coast

Sponsor
Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire (Other)
Overall Status
Recruiting
CT.gov ID
NCT05199831
Collaborator
Institute of Research for Development, France (Other), Institut de Sante Publique, d'Epidemiologie et de Developpement (Other), University of Toronto (Other), Université de Lille (Other)
450
2
10.8
225
20.8

Study Details

Study Description

Brief Summary

Background With the scale up of antiretroviral therapy (ART), people living with HIV (PLWHIV) life expectancy has increased dramatically over the last decades and HIV has become a chronic disease. However, the long-term infection with HIV is often associated with a number of health related challenges responsible of impairments and functional limitations. To achieve the ambitious objective that most of the PLWHIV receive ART and have a good quality of life, it is therefore necessary to address the HIV-related disability.

Objectives This research aims to provide a comprehensive analysis of the frequency and nature of the impairments and functional limitation occurring in PLWHIV, and of their impact on participants lives. It will also assess the level of physical activity and the acceptability of an intervention based on physical activity.

It will adopt a multidisciplinary approach, which will combine objective and subjective measurements of disability including bio-clinical data, epidemiological data and qualitative data reflecting PLWHIV's perspective. It will also include an evaluation of the a priori acceptability of using physical exercise with PLWHIV.

Three dimensions of disability will be considered in the analysis: 1) impairment and morbidities (neurological, motor and cognitive), 2) activities (or functional) limitations, 3) social participation restrictions. The evaluation of acceptability will cover perceived relevance, adequacy, perceived efficacy and easiness of use of the intervention Design and methods The quantitative evaluation will include 300 PLWHIV receiving ART and followed at the infectious disease department (SMIT), CHU de Treichville, Abidjan. A control group of HV uninfected adults will also be included (n = 150). This cross-sectional evaluation will combine clinical, functional and cognitive evaluations and questionnaire on disability (WHODAS, HDQ), depression (PHQ-9) and physical exercise acceptability.

The qualitative component will include around twenty PLWHIV. Participants will be selected to reflect the diversity of the population living with HIV (regarding sex, age, family situation). The qualitative research will be based on semi-directed interviews and will examine disability perception, biographic reconstruction after the onset of impairment and the acceptability of physical exercise.

Quantitative and qualitative researches will be integrated using an explanatory sequential design. The quantitative results will be used to the qualitative research questions sampling and design. In addition, results of the two components regarding the social participation and the perception and attitude toward physical activity will be integrated.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    450 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Cross-Sectional
    Official Title:
    Preliminary Situational Analysis of a Pilot Rehabilitation Intervention Based on Physical Exercise for People Living With HIV in Ivory Coast
    Actual Study Start Date :
    Feb 5, 2021
    Anticipated Primary Completion Date :
    Jan 1, 2022
    Anticipated Study Completion Date :
    Jan 1, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    Participants living with HIV

    Clinical, functional and cognitive evaluations; questionnaires on disability, social participation, mental health and physical activity

    Controls not infected with HIV

    Clinical, functional and cognitive evaluations; questionnaires on disability, social participation, mental health and physical activity

    Outcome Measures

    Primary Outcome Measures

    1. Functional capacity [Baseline]

      Short Physical Performance battery (SPPB)

    Secondary Outcome Measures

    1. Comorbidities: blood pressure [Baseline]

      Blood pressure

    2. Comorbidities: diabetes [Baseline]

      haemoglobin glycated

    3. Comorbidities: obesity [Baseline]

      Body mass index

    4. Neurologic outcomes CNS [Baseline]

      Central nervous system abnormality

    5. Neurologic outcomes BNPS [Baseline]

      Brief Peripheral Neuropathy Score (BNPS)

    6. Other functional scores: gate speed [Baseline]

      6 minutes walk test

    7. Other functional scores: motricity [Baseline]

      grooved pegboard test

    8. Other functional scores: strength [Baseline]

      grip strength

    9. Cognitive tests: color trail [Baseline]

      Color trail tests 1 & 2

    10. Cognitive tests: fluency test [Baseline]

      Category words fluency test

    11. Cognitive tests: DSST [Baseline]

      Digit symbol substitution test

    12. Cognitive tests: memory [Baseline]

      Grober & Buschke test

    13. Cognitive tests DST [Baseline]

      Digit span test

    14. Disability: WHODAS [Baseline]

      WHODAS-2

    15. Disability: HDQ [Baseline]

      HDQ-SF

    16. Disability: IADL [Baseline]

      IADL

    17. Physical activity [Baseline]

      GPAQ

    18. Mental health [Baseline]

      PHQ-9

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Age ≥40 years

    • HIV-1 infection (or negative HIV test within the last 12 months if control)

    • Ongoing antiretroviral treatment if HIV-infected participant

    Exclusion Criteria:
    • Clinical symptoms suggesting an acute infection

    • Any severe condition not allowing participation in the study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Centre National de Transfusion Sanguine Abidjan Côte D'Ivoire
    2 CHU Treichville Abidjan Côte D'Ivoire

    Sponsors and Collaborators

    • Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire
    • Institute of Research for Development, France
    • Institut de Sante Publique, d'Epidemiologie et de Developpement
    • University of Toronto
    • Université de Lille

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire
    ClinicalTrials.gov Identifier:
    NCT05199831
    Other Study ID Numbers:
    • VIRAGE
    First Posted:
    Jan 20, 2022
    Last Update Posted:
    Jan 20, 2022
    Last Verified:
    Dec 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 20, 2022